Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Original Article

AJVS. 2019; 63(1): 42-50


Ameliorative Effect of Trehalose on Liver Due to Doxorubicin-Induced Cardiomyopathy in Mice

Rasha Abu- Khudir, Afrah F. Salama, Wafaa M. Ibrahim, Mohammed E. Shams.

Abstract
Doxorubicin (DOX) is one of the most efficient anticancer chemotherapeutic drugs. However, its use is limited due to the induction of irreversible dilated cardiomyopathy and hepatotoxicity. The present study aimed to evaluate the hepatoprotective effect of trehalose (TRE) against DOX –induced cardiomyopathy(DIC). Mice were divided into five treated groups: Control group given saline, DOX group (2mg/kg body weight three times per week for three weeks day after day), TRE group (200µg/mouse three times per week for three weeks day after day), DOX+TRE cotreatment group (animals were co-administered 2mg/kg body weight of DOX with 200µg/mouse TRE by the same time), and DOX+TRE post treatment group (animals received 2mg/kg body weight DOX followed by treatment with 200µg/mouse TRE after 18 days). The obtained results indicated that DOX-treatment resulted in a decrease in body and liver weight ,and relative weight of liver compared to the control group. In addition, DOX-treatment caused an increase in activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST),and in level of hepatic malondialdehyde (MDA) concentration. However, concentration of total thiols (T-thiol), total antioxidant capacity (TAC) as well as catalase (CAT) enzyme activity were reduced in DOX-treated mice. Furthermore, dramatic changes in the histological architecture of the liver were observed. On the other hand, an improvement in the activities of ALT,AST, and CAT as well as levels of hepatic MDA ,T-thiol and TAC were observed in animals administrated with TRE either alone or in combination with DOX in cotreatment and post treatment groups in comparison with the ones treated with DOX alone. Moreover, histopathological examination of liver tissues in mice co-treated with DOX and TRE showed a significant improvement in hepatic parenchyma as compared to mice treated with DOX alone.

Key words: Doxorubicin; oxidative stress; cardiomyopathy; hepatotoxicity; trehalose.



Similar Articles

Adverse consequences of emotional support seeking through social network sites in coping with stress from a global pandemic.
Islam AKMN, Mäntymäki M, Laato S, Turel O
International journal of information management. 2022; 62(): 102431

Striatal oxidative damages and neuroinflammation correlate with progression and survival of Lewy body and Alzheimer diseases.
Li H, Knight WC, Xu J
Neural regeneration research. 2022; 17(4): 867-874

Sensory-processing sensitivity and COVID-19 stress in a young population: The mediating role of resilience.
Iimura S
Personality and individual differences. 2022; 184(): 111183

Family support and posttraumatic growth among tourism workers during the COVID-19 shutdown: The role of positive stress mindset.
Luu TT
Tourism management. 2022; 88(): 104399

The effects of listening to healing beat music on adults' recovery from exposure to stressful stimuli: A randomized controlled trial.
Bae IL, Kim YS, Hur MH
Integrative medicine research. 2022; 11(1): 100753


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.



ScopeMed Web Sites